Spruce Biosciences (SPRB)
(Delayed Data from NSDQ)
$0.70 USD
0.00 (-0.11%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $0.70 0.00 (-0.14%) 6:08 PM ET
2-Buy of 5 2
F Value C Growth F Momentum F VGM
Price, Consensus and EPS Surprise
SPRB 0.70 0.00(-0.11%)
Will SPRB be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SPRB based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SPRB
Spruce Biosciences (SPRB) Upgraded to Buy: Here's What You Should Know
Spruce Biosciences (SPRB) Falls 86% in a Month: Here's Why
SPRB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Spruce Biosciences, Inc. (SPRB) Upgraded to Buy: Here's Why
Spruce Biosciences, Inc. (SPRB) Upgraded to Buy: Here's What You Should Know
Spruce Biosciences, Inc. (SPRB) Now Trades Above Golden Cross: Time to Buy?
Other News for SPRB
Spruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
Spruce Biosciences announces upcoming poster presentation
Spruce Biosciences’ Compliance Hurdle: Navigating Sarbanes-Oxley to Protect Market Value
Analysts Offer Insights on Healthcare Companies: Terns Pharmaceuticals (TERN) and Spruce Biosciences (SPRB)
Why Limbach Holdings Shares Are Trading Lower By Around 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session